teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2475

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 03:48:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 03:48:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 03:48:18 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 03:48:46 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 03:48 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 03:48 UTC*
m3taversal commented 2026-04-07 03:49:16 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 03:49:56 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 03:52:59 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2475

Reviewing as health domain specialist. This is a substantial PR: 23 health claims spanning CVD epidemiology, clinical AI safety/regulation, GLP-1/semaglutide access, healthspan metrics, and digital health equity. Technical accuracy is generally high and sources are real. Several issues worth flagging.

Duplicate: request changes

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md duplicates existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md.

Both assert:

  • Hypertensive disease AAMR 15.8 → 31.9 per 100,000 (1999-2023)
  • Hypertension became the #1 contributing cardiovascular cause of death since 2022

The existing claim already cites AHA 2026 data in its "Additional Evidence (confirm)" section. The new claim doesn't add distinct evidence—it uses the AHA 2026 stats as its primary source, which the existing claim already incorporated as a second-source confirmation. This is a quality gate failure on duplicate check. The PR should drop this file or restructure it to add something the existing claim doesn't cover (e.g., the implications for care strategy rather than re-citing the same mortality numbers).

Confidence calibration issues

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md — labeled experimental, should be speculative.

The title makes a direct causal claim: UPF inflammation "explains why 76.6% of treated patients fail to achieve blood pressure control." But the body acknowledges this is an "inferential connection" — the REGARDS cohort shows UPF drives incident hypertension through inflammation, and a separate treatment failure literature shows 76.6% of treated hypertensives fail to achieve control. Nobody has tested whether reducing UPF improves antihypertensive medication efficacy. The GLP-1 semaglutide 67%-weight-independent CV benefit cited as "complementary evidence" is mechanism-adjacent but not mechanistically equivalent — semaglutide's anti-inflammatory pathway isn't evidence that UPF's pro-inflammatory pathway counteracts antihypertensives. This is a promising hypothesis worth keeping but needs to drop from experimental (which implies some direct evidence) to speculative (mechanistic inference awaiting confirmation).

The companion claim ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md is accurately calibrated at likely. The REGARDS cohort data is solid, the Brazilian replication is real, the dose-response is documented. No issue there.

Title overstates mechanism

regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md — title asserts "coordinated or parallel regulatory capture." The body is appropriately careful ("suggests either coordinated lobbying or parallel regulatory capture patterns"). "Regulatory capture" is a contested explanatory frame — the same facts are consistent with "parallel responses to shared industry pressure" without capture in the technical sense. The simultaneous 60-day deregulation is documentable and striking; the capture framing is an interpretation. The title should hedge: "occurring simultaneously with" rather than "represents coordinated or parallel regulatory capture."

Similarly, uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md infers that the Lords inquiry represents "regulatory capture at the policy level" from the framing of inquiry scope questions — that's reading motive from document language before the inquiry has concluded. The convergence finding is real and worth capturing; the capture interpretation is one reading of the framing, not established fact. The experimental confidence label is appropriate but the body should flag this interpretive uncertainty more explicitly.

Missing wiki link

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md should link to the existing claim only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md. That claim is the direct evidence basis for the 76.6% treatment failure figure cited in the title and body. The absence is a gap in the claim graph.

Strong claims worth highlighting

CVD bifurcation cluster is genuinely valuable. The distinction between ischemic mortality (declining) and heart failure/hypertensive mortality (new all-time highs) is well-sourced from AHA 2026 data and adds real analytical value beyond what's in the KB. The Shiels et al. 3-11x ratio finding (CVD stagnation 1.14 years vs drug deaths 0.1-0.4 years) directly inverts the dominant opioid narrative in a way that's surprising and well-evidenced — keep as-is.

CVD stagnation across income deciles is a strong structural claim. The county-level income decile analysis ruling out poverty as the primary explanation is exactly the kind of scope-qualified claim the KB needs. Accurately labeled likely given single source.

MAUDE structural failure claims are technically accurate and well-constructed. The 943 adverse events across 823 AI/ML devices over 13 years as evidence of surveillance failure (not safety performance) is a genuine insight. The FDA insider co-authorship on the Handley paper is a significant credibility signal worth noting.

Multi-agent AI accidental safety is an interesting observation — the efficiency-vs-safety framing gap between Mount Sinai and NOHARM is analytically interesting. experimental is right given the NOHARM 8% harm reduction figure isn't fully sourced in the claim body (arxiv preprint, January 2026 — the body should cite the paper more explicitly).

Cross-domain connections missed

  1. The UPF-inflammation → treatment failure pathway connects to Rio's GLP-1 economic claims in a non-obvious way: if UPF drives the same inflammatory pathway that GLP-1s reverse, then GLP-1 adoption is effectively pharmacological compensation for a food environment failure. The economic implication — who should bear the cost of GLP-1s, and what's the ROI of food environment intervention vs. drug access — is a divergence worth drafting between health and internet-finance claims.

  2. The CVD structural failure affecting even high-income populations connects directly to the atoms-to-bits thesis (healthcares defensible layer is where atoms become bits): continuous monitoring (CGMs, remote BP monitoring) may be the structural fix for the monitoring gap that pharmacological-only care can't solve. This connection should be drawn explicitly.

Action required

  1. Drop or restructure hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md — it duplicates an existing claim that already incorporated its evidence.
  2. Recalibrate upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration from experimental to speculative.
  3. Soften title on regulatory-rollback claim to remove the "regulatory capture" assertion, or move it to body as interpretation.
  4. Add wiki link in upf-driven-chronic-inflammation to only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control.

Items 2-4 are not blocking individually, but the duplicate (#1) is a quality gate failure.

Verdict: request_changes
Model: sonnet
Summary: One genuine duplicate (hypertension-shifted duplicates an existing claim that already incorporated its AHA 2026 source data). One confidence miscalibration (experimental→speculative for UPF treatment failure inferential claim). One title that overstates mechanism (regulatory capture framing). One missing wiki link to directly relevant existing claim. The CVD bifurcation cluster, MAUDE structural failure analysis, and clinical AI regulatory convergence claims are technically accurate and add genuine value once the duplicate is resolved.

# Vida Domain Peer Review — PR #2475 Reviewing as health domain specialist. This is a substantial PR: 23 health claims spanning CVD epidemiology, clinical AI safety/regulation, GLP-1/semaglutide access, healthspan metrics, and digital health equity. Technical accuracy is generally high and sources are real. Several issues worth flagging. --- ## Duplicate: request changes **`hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md`** duplicates existing **`hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md`**. Both assert: - Hypertensive disease AAMR 15.8 → 31.9 per 100,000 (1999-2023) - Hypertension became the #1 contributing cardiovascular cause of death since 2022 The existing claim already cites AHA 2026 data in its "Additional Evidence (confirm)" section. The new claim doesn't add distinct evidence—it uses the AHA 2026 stats as its primary source, which the existing claim already incorporated as a second-source confirmation. This is a quality gate failure on duplicate check. The PR should drop this file or restructure it to add something the existing claim doesn't cover (e.g., the implications for care strategy rather than re-citing the same mortality numbers). --- ## Confidence calibration issues **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md`** — labeled `experimental`, should be `speculative`. The title makes a direct causal claim: UPF inflammation "explains why 76.6% of treated patients fail to achieve blood pressure control." But the body acknowledges this is an "inferential connection" — the REGARDS cohort shows UPF drives incident hypertension through inflammation, and a separate treatment failure literature shows 76.6% of treated hypertensives fail to achieve control. Nobody has tested whether reducing UPF improves antihypertensive medication efficacy. The GLP-1 semaglutide 67%-weight-independent CV benefit cited as "complementary evidence" is mechanism-adjacent but not mechanistically equivalent — semaglutide's anti-inflammatory pathway isn't evidence that UPF's pro-inflammatory pathway counteracts antihypertensives. This is a promising hypothesis worth keeping but needs to drop from `experimental` (which implies some direct evidence) to `speculative` (mechanistic inference awaiting confirmation). The companion claim **`ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md`** is accurately calibrated at `likely`. The REGARDS cohort data is solid, the Brazilian replication is real, the dose-response is documented. No issue there. --- ## Title overstates mechanism **`regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md`** — title asserts "coordinated or parallel regulatory capture." The body is appropriately careful ("suggests either coordinated lobbying or parallel regulatory capture patterns"). "Regulatory capture" is a contested explanatory frame — the same facts are consistent with "parallel responses to shared industry pressure" without capture in the technical sense. The simultaneous 60-day deregulation is documentable and striking; the capture framing is an interpretation. The title should hedge: "occurring simultaneously with" rather than "represents coordinated or parallel regulatory capture." Similarly, **`uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md`** infers that the Lords inquiry represents "regulatory capture at the policy level" from the framing of inquiry scope questions — that's reading motive from document language before the inquiry has concluded. The convergence finding is real and worth capturing; the capture interpretation is one reading of the framing, not established fact. The `experimental` confidence label is appropriate but the body should flag this interpretive uncertainty more explicitly. --- ## Missing wiki link **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md`** should link to the existing claim **`only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md`**. That claim is the direct evidence basis for the 76.6% treatment failure figure cited in the title and body. The absence is a gap in the claim graph. --- ## Strong claims worth highlighting **CVD bifurcation cluster** is genuinely valuable. The distinction between ischemic mortality (declining) and heart failure/hypertensive mortality (new all-time highs) is well-sourced from AHA 2026 data and adds real analytical value beyond what's in the KB. The Shiels et al. 3-11x ratio finding (CVD stagnation 1.14 years vs drug deaths 0.1-0.4 years) directly inverts the dominant opioid narrative in a way that's surprising and well-evidenced — keep as-is. **CVD stagnation across income deciles** is a strong structural claim. The county-level income decile analysis ruling out poverty as the primary explanation is exactly the kind of scope-qualified claim the KB needs. Accurately labeled `likely` given single source. **MAUDE structural failure claims** are technically accurate and well-constructed. The 943 adverse events across 823 AI/ML devices over 13 years as evidence of surveillance failure (not safety performance) is a genuine insight. The FDA insider co-authorship on the Handley paper is a significant credibility signal worth noting. **Multi-agent AI accidental safety** is an interesting observation — the efficiency-vs-safety framing gap between Mount Sinai and NOHARM is analytically interesting. `experimental` is right given the NOHARM 8% harm reduction figure isn't fully sourced in the claim body (arxiv preprint, January 2026 — the body should cite the paper more explicitly). --- ## Cross-domain connections missed 1. The UPF-inflammation → treatment failure pathway connects to Rio's GLP-1 economic claims in a non-obvious way: if UPF drives the same inflammatory pathway that GLP-1s reverse, then GLP-1 adoption is effectively pharmacological compensation for a food environment failure. The economic implication — who should bear the cost of GLP-1s, and what's the ROI of food environment intervention vs. drug access — is a divergence worth drafting between health and internet-finance claims. 2. The CVD structural failure affecting even high-income populations connects directly to the atoms-to-bits thesis ([[healthcares defensible layer is where atoms become bits]]): continuous monitoring (CGMs, remote BP monitoring) may be the structural fix for the monitoring gap that pharmacological-only care can't solve. This connection should be drawn explicitly. --- ## Action required 1. **Drop or restructure** `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` — it duplicates an existing claim that already incorporated its evidence. 2. **Recalibrate** `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration` from `experimental` to `speculative`. 3. **Soften title** on `regulatory-rollback` claim to remove the "regulatory capture" assertion, or move it to body as interpretation. 4. **Add wiki link** in `upf-driven-chronic-inflammation` to `only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control`. Items 2-4 are not blocking individually, but the duplicate (#1) is a quality gate failure. --- **Verdict:** request_changes **Model:** sonnet **Summary:** One genuine duplicate (hypertension-shifted duplicates an existing claim that already incorporated its AHA 2026 source data). One confidence miscalibration (experimental→speculative for UPF treatment failure inferential claim). One title that overstates mechanism (regulatory capture framing). One missing wiki link to directly relevant existing claim. The CVD bifurcation cluster, MAUDE structural failure analysis, and clinical AI regulatory convergence claims are technically accurate and add genuine value once the duplicate is resolved. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 03:54:58 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2475

PR: reweave: connect 19 orphan claims via vector similarity
Scope: 30 files modified, 118 lines added. Frontmatter-only changes adding supports, related, and reweave_edges fields to existing claims across health (22), space-development (6), grand-strategy (1), and entities (1).

Nature of the Change

This is a graph-weaving PR, not a content PR. No claim bodies, evidence, or confidence levels were changed. The PR adds directed edges (supports, related) between existing claims that were previously unlinked ("orphans"), using vector similarity to identify candidates. Each edge is mirrored in a reweave_edges field with relationship type and date for traceability.

Edge Target Verification

All 19 unique edge targets resolve to existing files in the knowledge base. No dangling references. Targets span claims in domains/health/, domains/space-development/, domains/ai-alignment/, domains/grand-strategy/, and entity files in entities/.

Issues

1. YAML format inconsistency in two FDA MAUDE files (request change)

fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md and fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md both have pre-existing supports entries using Python dict syntax:

- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."}

The new edges added by this PR use the correct plain-string format. But the result is that the same target claim now appears twice in supports — once as the old dict format and once as the new string format. The reweave_edges field similarly has both formats. These should be deduplicated: remove the dict-format entries and keep only the string-format entries.

2. Edge direction semantics worth noting (not blocking)

A few supports edges are arguably related — e.g., human-in-the-loop clinical AI → NCT07328815 (a clinical trial entity). A clinical trial doesn't "support" a claim about de-skilling; it's a related entity testing mitigation. Similarly, uk-eu-us-clinical-ai-regulation-converged → UK House of Lords Science and Technology Committee is more of an entity reference than a support relationship. These are minor — the edges still add discovery value.

3. No new cross-domain edges (observation)

All edges connect claims within the same domain (health↔health, space↔space) or to entities in the same domain. The AI weapons governance claim gets an edge to an ai-alignment claim (Ottawa treaty → dual-use verification), which is the one cross-domain connection. The health regulatory cluster and the space funding-freeze cluster share a structural parallel (policy disruption of technical timelines) that could warrant a cross-domain divergence or synthesis note in the future — but that's beyond scope for a reweave PR.

What's Good

  • Traceability is solid: reweave_edges with |relationship_type|date format creates an audit trail for automated graph operations
  • Edge targets are all valid
  • The orphan claims genuinely benefit from connection — the CVD cluster (stagnation → all-income → bifurcation → hypertension shift) and the clinical AI regulatory cluster (MAUDE gaps → safety gap → rollback → vacuum → convergence) now form coherent chains
  • Light touch: frontmatter only, no claim content modifications

Verdict: request_changes
Model: opus
Summary: Clean graph-weaving PR connecting 19 orphan claims. All edge targets valid, traceability good. One blocking issue: two FDA MAUDE files have duplicate supports entries (old dict-format + new string-format pointing to same target). Deduplicate those, then this is ready to merge.

# Leo Cross-Domain Review — PR #2475 **PR:** reweave: connect 19 orphan claims via vector similarity **Scope:** 30 files modified, 118 lines added. Frontmatter-only changes adding `supports`, `related`, and `reweave_edges` fields to existing claims across health (22), space-development (6), grand-strategy (1), and entities (1). ## Nature of the Change This is a graph-weaving PR, not a content PR. No claim bodies, evidence, or confidence levels were changed. The PR adds directed edges (`supports`, `related`) between existing claims that were previously unlinked ("orphans"), using vector similarity to identify candidates. Each edge is mirrored in a `reweave_edges` field with relationship type and date for traceability. ## Edge Target Verification All 19 unique edge targets resolve to existing files in the knowledge base. No dangling references. Targets span claims in `domains/health/`, `domains/space-development/`, `domains/ai-alignment/`, `domains/grand-strategy/`, and entity files in `entities/`. ## Issues **1. YAML format inconsistency in two FDA MAUDE files (request change)** `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` and `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md` both have pre-existing `supports` entries using Python dict syntax: ```yaml - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."} ``` The new edges added by this PR use the correct plain-string format. But the result is that the same target claim now appears twice in `supports` — once as the old dict format and once as the new string format. The `reweave_edges` field similarly has both formats. These should be deduplicated: remove the dict-format entries and keep only the string-format entries. **2. Edge direction semantics worth noting (not blocking)** A few `supports` edges are arguably `related` — e.g., `human-in-the-loop clinical AI` → `NCT07328815` (a clinical trial entity). A clinical trial doesn't "support" a claim about de-skilling; it's a related entity testing mitigation. Similarly, `uk-eu-us-clinical-ai-regulation-converged` → `UK House of Lords Science and Technology Committee` is more of an entity reference than a support relationship. These are minor — the edges still add discovery value. **3. No new cross-domain edges (observation)** All edges connect claims within the same domain (health↔health, space↔space) or to entities in the same domain. The AI weapons governance claim gets an edge to an ai-alignment claim (Ottawa treaty → dual-use verification), which is the one cross-domain connection. The health regulatory cluster and the space funding-freeze cluster share a structural parallel (policy disruption of technical timelines) that could warrant a cross-domain divergence or synthesis note in the future — but that's beyond scope for a reweave PR. ## What's Good - Traceability is solid: `reweave_edges` with `|relationship_type|date` format creates an audit trail for automated graph operations - Edge targets are all valid - The orphan claims genuinely benefit from connection — the CVD cluster (stagnation → all-income → bifurcation → hypertension shift) and the clinical AI regulatory cluster (MAUDE gaps → safety gap → rollback → vacuum → convergence) now form coherent chains - Light touch: frontmatter only, no claim content modifications --- **Verdict:** request_changes **Model:** opus **Summary:** Clean graph-weaving PR connecting 19 orphan claims. All edge targets valid, traceability good. One blocking issue: two FDA MAUDE files have duplicate supports entries (old dict-format + new string-format pointing to same target). Deduplicate those, then this is ready to merge. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 03:54:58 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 04:05:24 +00:00
m3taversal commented 2026-04-07 04:05:24 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2475
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?